Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of fadanafil tablets for symptoms and signs of benign prostatic hyperplasia
CTR20250025Phase 2Active
- Sponsor
- Xuanzhu Biopharmaceutical
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Fadanafil in benign prostatic hyperplasia (BPH), sponsored by Xuanzhu Biopharmaceutical. Started Jan 2025; status: active.
02
Drugs
Fadanafil
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on CTR20250025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250025.